Discusses strategies to overcome the blood-brain-barrier
Comparative evaluation of the present state of drug delivery strategies
Biological carriers, prodrug and chemical delivery/targeting strategies are presented
Various peptides native to the brain and the spinal cord, as well as various synthetic peptides, peptide analogues and peptidomimetics could be useful in the treatment of diseases of the central nervous system. This book provides an overview of the role and neuropharmaceutical potential of these peptides, and discusses the state of the art and future trends in the use of peptide pharmacotherapy involving the brain.
Neuropeptides: general characteristics and neuropharmaceutical potential in treating CNS disorders.- Structural and functional aspects of the blood-brain barrier.- Peptide transport across the blood-brain barrier.- Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases.- Altering the properties of the blood-brain barrier: disruption and permeabilization.- Modifying peptide properties by prodrug design for enhanced transport into the CNS.- CNS-delivery via conjugation to biological carriers: physiological-based approaches.- Peptide vectors as drug carriers.- Index Vol. 61.
Hypo- or hypersecretion, alteration in storage, release, catabolism, and post-translational processing of neuropeptides are associated with the etiology of many diseases affecting the central nervous system (CNS). Various peptides native to the brain and the spinal cord, as well as various synthetic peptides, peptide analogues and peptidomimetics developed as their agonists or antagonists could be useful in the treatment of these CNS maladies. However, peptides face a formidable obstacle in reaching the intended site of action due to the existence of the blood-brain barrier (BBB), a vital element in the regulation of the internal environment of the brain and the spinal cord. After reviews on the role and neuropharmaceutical potential of peptides, properties of the BBB in the context of peptide transport in the CNS and potential transport mechanisms to cross the BBB, this volume discusses the development, present state-of-the-art and future trends of various strategies to overcome this major obstacle to peptide pharmacotherapy involving the CNS. Chapters are devoted to cover invasive approaches that circumvent the BBB by direct administration into the brain or the spinal cord and by transiently opening the tight junctions of or permeabilizing the endothelial cells separating the systemic circulation from the interstitial fluid of the CNS. Subsequently, physiologically based strategies that utilize biological carriers to gain access to the CNS are discussed in detail, followed by methods encompassing prodrug and chemical delivery/targeting strategies, which aim at altering the properties of the peptide to enhance BBB transport, and drug delivery strategies based on peptide vectors. Finally, a comparative evaluation on the present status and perspectives of the techniques is presented.
Inhaltsverzeichnis
Neuropeptides: general characteristics and neuropharmaceutical potential in treating CNS disorders.- Structural and functional aspects of the blood-brain barrier.- Peptide transport across the blood-brain barrier.- Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases.- Altering the properties of the blood-brain barrier: disruption and permeabilization.- Modifying peptide properties by prodrug design for enhanced transport into the CNS.- CNS-delivery via conjugation to biological carriers: physiological-based approaches.- Peptide vectors as drug carriers.- Index Vol. 61.
Klappentext
The general characteristics of neuropeptides are discussed as a background for the understanding of their role in regulation of physiological systems. The extent of those systems that are crucially affected by neuropeptides is vast and the complexity of their interactions makes the clinical focus on a specific neu ropeptide unsatisfactory. The clinical potential of neuropeptides affecting eating disorders, eNS behavioral disorders and the neuroregenerative and neuroprotective action of neuropeptides is discussed. It is probable that suc cessful neuropeptide therapeutics will depend upon the application of trans lational and combinational research using various ingenious combinations and antagonists, neuropeptide receptor ago of neuropeptides, their agonists nists and antagonists, improved methods of delivery and the development of peptides targeted to the genetic profile of individual patients. References 1 DeWied D (1969) Effects of peptide hormones on behavior. In: WF Ganong, L Martini (eds): Frontiers in Neuroendocrinology. Oxford University Press, New York, 97-140 2 Sandman CA, Schally AV, Kastin AJ, Miller L H (1972) A neuroendocrine influence on attention and memory. J Comp Physiol Psychol80: 54-58 3 Kastin AJ, Olson RD, SchaUy A V, Coy DH (1979) CNS effects of peripherally adminis tered brain peptides. Life Sci 25: 401-414 4 Strand FL, Saint-Come C, Lee TS, Lee SJ, Kume JA, Zuccarelli LA (1993) An ACTH/MSH 4-10 analog BIM 22015 has neurotrophic and myotrophic attributes during peripheral nerve regeneration. Peptides 14: 287-296 5 Strand FL (1999) Neuropeptides: Regulators ofPhysiologjcal Processes.
Various peptides native to the brain and the spinal cord, as well as various synthetic peptides, peptide analogues and peptidomimetics could be useful in the treatment of diseases of the central nervous system. This book provides an overview of the role and neuropharmaceutical potential of these peptides, and discusses the state of the art and future trends in the use of peptide pharmacotherapy involving the brain.
